Patient cell drug profiling identifies p53-linked vulnerabilities in refractory lymphoid malignancies
Relapsed/refractory lymphoid malignancies lack effective treatment selection strategies. We evaluated high-throughput ex vivo drug profiling in 26 patients, achieving successful profiling in 22 cases. We found broad ex vivo resistance to conventional chemotherapy but sensitivity to BH3 mimetics. Notably, p53-aberrant samples showed increased sensitivity to dasatinib and PI3K inhibitors across subtypes. These findings demonstrate feasibility of functional precision medicine pipelines in lymphoid malignancies and identify actionable vulnerabilities warranting further investigation.
Authors
- Tom Erkers (ORCID: https://orcid.org/0000-0002-2754-6287)
- Nona Struyf (ORCID: https://orcid.org/0000-0002-6975-0753)
- Kristina Sonnevi (ORCID: https://orcid.org/0000-0002-7306-2371)
- Arvid Cederlund
- L. Pizarro
- Björn E. Wahlin (ORCID: https://orcid.org/0000-0003-3566-8847)
- Päivi Östling (ORCID: https://orcid.org/0000-0001-5501-466X)
Institutions
- Karolinska University Hospital (SE)
- Science for Life Laboratory (SE)
- Karolinska Institutet (SE)
Publication Details
- Journal
- npj Precision Oncology
- Published
- 2026-07-30
- DOI
- https://doi.org/10.1038/s41698-026-01630-8
- Primary Topic
- Cancer-related Molecular Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Commission
- Svenska Forskningsrådet Formas
- Karolinska Institutet
- Vetenskapsrådet
- Stiftelsen Konung Gustaf V:s Jubileumsfond